Olutayo E et al., 2026-01: Retrospective institutional review at MD Anderson of patients who self-reported taking these drugs: 182 patients took fenbendazole (0.06% of 297,223 patients seen 2020-2024), reporting 138 different doses and frequencies, most often in metastatic, prostate and colorectal cancer.
We identified 499 patients taking ivermectin and 182 patients taking fenbendazole as supplemental therapy at MDACC.
Abstract 818
Olutayo E et al., 2026-01: Retrospective institutional review at MD Anderson of patients who self-reported taking these drugs: 182 patients took fenbendazole (0.06% of 297,223 patients seen 2020-2024), reporting 138 different doses and frequencies, most often in metastatic, prostate and colorectal cancer. Study type: retrospective review of self-reported non-prescription use in the electronic record (SAP Webi query), n=182 fenbendazole users and 499 ivermectin users out of 297,223 patients seen at MD Anderson, January 2020 to January 2024, USA. Fenbendazole users per year 2020-2024: 42, 47, 42, 51. Dose: not standardised – 'There were 154 and 138 different dosages and frequencies of ivermectin and fenbendazole reported by patients, respectively'; the abstract does not list them. No MDACC prescription was issued for either drug. Funder and conflicts: not stated in the abstract. Comparator: none. Outcome: no clinical outcome reported; this is a utilisation study. The ASCO and Ovid pages are Cloudflare/bot-walled; the same abstract text was read on MD Anderson's own institutional repository (Elsevier Pure), which is cited here. Study type: other.
